Biogen Idec (BIIB - Analyst Report) and Abbott Labs (ABT -Analyst Report) recently presented positive top-line data on their multiple sclerosis candidate, daclizumab. Biogen and Abbott Labs presented data from a phase IIb study – SELECT.
The global, randomized, double-blind, placebo-controlled, one-year, dose-ranging study was conducted to evaluate the safety and efficacy of daclizumab in 600 patients with relapsing-remitting multiple sclerosis (RRMS).
Two doses (150 mg or 300 mg every four weeks) of daclizumab were evaluated. Results showed that daclizumab reduced the annualized relapse rate by 54% in the 150 mg dose and 50% in the 300 mg dose arm compared to placebo.
Key secondary endpoints were also achieved by the candidate. The study also investigated daclizumab’s effect on disability progression as measured by the expanded disability status scale (EDSS) as a tertiary endpoint. Results showed that daclizumab reduced the risk of sustained disability progression at one year by 57% and 43% in the 150 mg and 300 mg dose arms, respectively. Biogen and Abbott Labs are currently analyzing the data further and expect to present detailed results at an upcoming medical meeting
Read More
..
===========================================================
Remain CURRENT with Multiple Sclerosis news and information,
when registered at our MS Views and News website
.
.Providing You with 'MS Views and News', is what we do
.
On the 4th Wednesday of each month
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions
.
Your donation will Help us to educate
"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service
.. All contributions are tax deductible to the fullest extent allowed by law
.===========================================================
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
0 comments:
Post a Comment